Key Takeaways
- Record margins, steady growth: Revenue grew 9% YoY to INR1,094 crore while EBITDA margin hit a best-ever 30.2%, up 120 bps YoY, driven by a 210 bps gross margin expansion and a favorable domestic mix.
- Domestic business is the engine: 14% YoY growth with volume growth 350 bps above the market, powered by chronic therapies, ophthalmology, and flagship brands like Sporlac and Razel crossing major milestones.
- Torrent acquisition defines the future: Torrent Pharma's announced acquisition of KKR's 46.39% controlling stake and subsequent merger creates a diversified platform; the deal is subject to regulatory approvals and management declined to comment beyond the press release.
- International business is a drag, with a promised H2 recovery: International formulations declined 2% YoY on softness in Russia, South Africa, and the U.S., while CDMO grew only 8% against a 12-14% full-year guide; management expects a second-half ramp.
- What to watch next quarter: Whether CDMO growth accelerates toward the guided 12-14% range, the pace of international branded generic recovery, and any regulatory milestones on the Torrent merger.
Domestic Business: Volume-Led Outperformance
- Broad-based volume premium: Domestic volume growth of 4%+ ran 350 bps ahead of the 1.5% market volume growth, with the 14% overall growth split evenly between price (7%) and volume (7%).
- Chronic portfolio momentum: Chronic therapies grew 15% YoY per IQVIA, sustaining a multi-quarter trend and reinforcing the portfolio's strategic tilt toward chronic.
- Acute rebound led by probiotics: Acute business grew 12% YoY per IQVIA, driven by high-teen growth in Sporlac and newer probiotic versions, while legacy brands Rantac and Metrogyl remained flat.
- Ophthalmology scaling fast: The portfolio grew 19% YoY per IQVIA, lifting the quarterly run rate from ~INR40 crore to ~INR50 crore; legacy brands like Vigamox and Vigadexa delivered double-digit growth, and the company now ranks sixth in the segment.
- Sporlac doubles in three years: The franchise grew from INR70 crore (June 2022) to INR146 crore (MAT June 2025) and recently entered the top 300 brands list in India.
- Razel crosses INR100 crore: The franchise reached INR100 crore MAT from INR69 crore at acquisition 24 months ago, with statin value addition and lipid-side work driving productivity among cardiologists and physicians.
- Azmarda scaling toward target: The heart failure brand hit INR75 crore and reached the 120,000-125,000 units/month target; the next milestone is 140,000 units/month in 3-4 months, with operating leverage improving as scale builds.
- Cilacar T enters top 100: The brand entered the top 100 brands in India in June on a monthly basis, growing at ~20% plus, with market therapy shaping work expanding the Cilnidipine plus ARB segment for diabetic hypertension.
Kunal Khanna: "Our volume growth has been 350 bps higher than the market, while the market volume growth as per MAT June was close to 1.5%, we have registered 4% plus."
Torrent Acquisition: Platform Creation, Limited Disclosure
- The transaction: On June 29, Torrent Pharma announced its intention to acquire KKR's 46.39% controlling stake in J.B. Pharma for INR11,917 crore, followed by a merger of J.B. Pharma into Torrent, with a tender offer price of INR1,639.18 per share. The deal is subject to CCI and other regulatory approvals.
- Strategic rationale: The combination creates a diversified healthcare platform with deep capabilities in chronic therapies and the international CDMO segment, per the CEO.
- Management boundary: When asked about acquisition milestones and whether the deal would conclude within the fiscal year, management declined to comment beyond the press release, calling further detail "very difficult."
Nikhil Chopra: "The transaction creates a diversified health care platform with deep capabilities in chronic and international CDMO segment."
International Business: Soft Q1, H2 Recovery Expected
- International formulations declined 2% YoY to INR283 crore, with Russia hurt by a slow season, South Africa seeing muted growth in private and large institutional accounts, and the U.S. flat to marginally down.
- CDMO grew only 8% YoY against a full-year guidance of 12-14%, though first commercial quantities of new products (Iodine Liquid, Throat Spray, Immunity Lozenges variants) were dispatched to Asia Pac and EU markets.
- The H2 ramp bet: Management expects international branded generics to reach high single-digit growth by end of Q3, with Russia demand picking up from September and South Africa benefiting from grants and sanctions in H2. CDMO visibility is good for Q2, with the H1 average run rate at ~INR120 crore and H2 closer to INR130 crore.
- ROW market expansion begins Q4: The first phase of pipeline approvals kicks off from September/October, covering 8-10 molecules across 14-16 key markets; launch quantities flow from Q4 FY26, with full annualized commercial benefit in FY27.
- API vertical surged 38% YoY to INR18 crore, driven largely by captive consumption demand that was pushed from last year due to high inventory, plus positive diclofenac API export offtake in Q1.
- U.S. disclosure declined: Management refused to provide a quarterly U.S. sales run rate, stating, "We generally don't get into those kind of segment-wise disclosures."
Margins: Record Highs with Cost Discipline
- Gross margin expanded 210 bps YoY to 68.3%, aided by price growth, cost optimization initiatives, and a favorable business mix.
- EBITDA margin reached a best-ever 30.2%, up 120 bps YoY, reflecting a focus on profitable growth even as employee expenses rose 16% YoY on increments and field incentives, not headcount expansion.
- One-off integration costs: Other expenses rose 16% YoY, including INR15 crore in one-off charges related to the proposed merger scheme; an analyst noted Torrent also booked INR15 crore, totaling ~INR30 crore in integration expenses, though management confirmed only their own portion.
- Full-year margin guidance maintained at 27-29% EBITDA, with management aiming for the top percentile of that range, consistent with historical practice.
- Gross margin guidance held at 67% for the full year.
- Operating cash flow is expected at 75-78% of operating EBITDA for FY26.
Nikhil Chopra: "30.2%, our EBITDA margins are the best up till now what we have been reported."
CDMO & New Launches: Building the Pipeline
- 3-4 important new CDMO launches are expected in the next 12-18 months, adding to the first commercial dispatches already completed in Q1.
- Run-rate trajectory: The CDMO business is expected to average ~INR120 crore per quarter in H1, step up to ~INR130 crore in H2, and enter next year at a INR140-145 crore starting run rate, supporting the 12-14% full-year growth guide.
- New product dispatches: Iodine Liquid, Throat Spray, and variants of Immunity Lozenges were shipped to Asia Pac and EU markets in their first commercial quantities, marking an expansion of the CDMO product portfolio.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Domestic revenue growth | 12-14% growth, 300-400 bps above market | FY26 |
| CDMO revenue growth | 12-14% growth; H2 run rate ~INR130 crore | FY26 |
| International branded generics | High single-digit growth | By end of Q3 FY26 |
| Gross margin | Maintain at 67% | FY26 |
| EBITDA margin | 27-29%, aim for top percentile of range | FY26 |
| Operating cash flow | 75-78% of operating EBITDA | FY26 |
| Azmarda volume | Reach 140,000 units per month | Next 3-4 months |
| ROW market launches | Launch quantities of 8-10 molecules across 14-16 markets | Q4 FY26 |
| CDMO new launches | 3-4 important new launches | Next 12-18 months |
| Ophthalmology ranking | Move from 6th to top 5 | 9 months to a year |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Revenue | ₹1,094 cr, +9% YoY |
| Domestic revenue | ₹678 cr, +14% YoY |
| International revenue | ₹416 cr, +2% YoY |
| Gross margin | 68.3%, +210 bps YoY from 66.2% |
| Operating EBITDA (excl. ESOP and one-off) | ₹330 cr, +13% YoY |
| Operating EBITDA margin (excl. ESOP and one-off) | 30.2%, +120 bps YoY from 29% |
| Net profit (excl. one-off) | ₹214 cr, +21% YoY |
| PAT margin (excl. one-off) | 19.6% |
| Domestic growth per IQVIA | 13%, vs industry 9% |
| Chronic portfolio growth per IQVIA | 15% YoY |
| Acute portfolio growth per IQVIA | 12% YoY |
| Ophthalmology portfolio growth per IQVIA | 19% YoY |
| CDMO revenue | ₹115 cr, +8% YoY |
| International Formulations revenue | ₹283 cr, -2% YoY from ₹290 cr |
| API revenue | ₹18 cr, +38% YoY |
| CDMO full-year growth guidance | 12% to 14% |
| Domestic full-year growth guidance | 300–400 bps above market growth |
| Full-year gross margin guidance | 67% |
| Full-year operating EBITDA margin guidance | 27% to 29% |
| Sporlac franchise size (MAT June 2025) | ₹146 cr, up from ₹70 cr in June 2022 |
| Azmarda brand size | ₹75 cr |
| Razel franchise size (MAT June 2025) | crossed ₹100 cr, up from ₹69 cr in June 2023 |
| One-off merger scheme charges | ₹15 cr |
| Operating cash flow guidance (full year) | 75% to 78% of operating EBITDA |